Analysts expect Quidel Co. (NASDAQ:QDEL) to report earnings per share (EPS) of $0.78 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Quidel’s earnings, with the lowest EPS estimate coming in at $0.74 and the highest estimate coming in at $0.87. Quidel posted earnings of $0.80 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 2.5%. The company is expected to issue its next quarterly earnings results on Wednesday, February 12th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that Quidel will report full year earnings of $2.74 per share for the current year, with EPS estimates ranging from $2.70 to $2.84. For the next fiscal year, analysts anticipate that the company will report earnings of $3.15 per share, with EPS estimates ranging from $2.89 to $3.57. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Quidel.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.06. The company had revenue of $126.50 million for the quarter, compared to analyst estimates of $125.52 million. Quidel had a net margin of 14.51% and a return on equity of 22.48%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share.
Several equities analysts have recently issued reports on QDEL shares. TheStreet raised shares of Quidel from a “c+” rating to a “b” rating in a report on Friday, November 1st. ValuEngine raised shares of Quidel from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Craig Hallum raised shares of Quidel from a “hold” rating to a “buy” rating and boosted their price target for the company from $63.00 to $75.00 in a report on Thursday, August 29th. Finally, Zacks Investment Research raised shares of Quidel from a “sell” rating to a “hold” rating in a report on Friday. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Quidel currently has a consensus rating of “Buy” and an average price target of $73.00.
In related news, Director Kenneth F. Buechler sold 4,000 shares of Quidel stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $68.86, for a total transaction of $275,440.00. Following the sale, the director now directly owns 54,433 shares in the company, valued at $3,748,256.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Douglas C. Bryant sold 71,708 shares of Quidel stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $62.18, for a total transaction of $4,458,803.44. Following the sale, the chief executive officer now owns 326,692 shares in the company, valued at $20,313,708.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 118,361 shares of company stock worth $312,782,451. Company insiders own 14.10% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its stake in shares of Quidel by 190.1% during the second quarter. Tower Research Capital LLC TRC now owns 589 shares of the company’s stock valued at $35,000 after purchasing an additional 386 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Quidel by 300.0% during the third quarter. Nisa Investment Advisors LLC now owns 760 shares of the company’s stock valued at $47,000 after purchasing an additional 570 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Quidel during the third quarter valued at about $110,000. Prudential Financial Inc. raised its stake in shares of Quidel by 7.6% during the second quarter. Prudential Financial Inc. now owns 3,837 shares of the company’s stock valued at $228,000 after purchasing an additional 270 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in shares of Quidel during the second quarter valued at about $234,000. Institutional investors and hedge funds own 90.10% of the company’s stock.
Shares of QDEL traded up $0.80 during mid-day trading on Friday, reaching $59.55. 132,900 shares of the stock traded hands, compared to its average volume of 208,108. Quidel has a 12-month low of $44.27 and a 12-month high of $70.31. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of 21.12 and a beta of 1.41. The company has a quick ratio of 0.83, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $59.97 and a 200 day simple moving average of $59.45.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Featured Story: What does it mean to hold a stock in street name?
For more information about research offerings from Zacks Investment Research, visit Zacks.com